Macrophage migration inhibitory factor in cancer

Yasasever V., Camlica H., Duranyildiz D., Oguz H., Tas F., Dalay N.

CANCER INVESTIGATION, vol.25, no.8, pp.715-719, 2007 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 25 Issue: 8
  • Publication Date: 2007
  • Doi Number: 10.1080/07357900701560695
  • Journal Name: CANCER INVESTIGATION
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.715-719
  • Keywords: MIF, colorectal cancer, malignant melanoma, tumor marker, ELISA, FACTOR MIF, COLORECTAL-CANCER, HEPATOCELLULAR-CARCINOMA, PROSTATIC ADENOCARCINOMA, BREAST-CANCER, CELL-GROWTH, EXPRESSION, ANGIOGENESIS, HYPERSENSITIVITY, MELANOMA
  • Istanbul University Affiliated: Yes

Abstract

The objective of this study was to investigate the expression of macrophage migration inhibitory factor (MIF) in patients with colorectal cancer (GIS) and malignant melanoma (MM). The study group consists of pathologically verified colorectal cancer (n = 63) and malignant melanoma (n = 65) pateints and healthy controls (n = 25). Serum MIF concentrations were determined by enyzme-linked immunosorbent assay. Serum values of the patients were significantly higher than the controls (p < 0.001 for GIS, p = 0.032 for MM). Diagnostic sensitivity and specificity were calculated for MIF for colorectal and malignant melanoma. The results demonstrate that colorectal cancer express and secrete large amounts of MIF.